Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.7.7 (
DNA polymerase
)
17,007
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A intertypic recombinant, designated HSV-R(D1), had previously been generated from non-neuroinvasive HSV-2(186) and neuroinvasive HSV-1(17). Although the recombinant contained less than 2% of the HSV-1 genome, it retained the neuroinvasive phenotype. The nucleotide sequences responsible for the neuroinvasiveness of HSV-R(D1) were previously mapped to a 3.0 kb segment of DNA located within the
DNA polymerase
gene (mu 0.414 to 0.430) via marker rescue experiments. We have now sequenced this region and compared our results to the published nucleotide sequence of the HSV-1(17) and HSV-2(186)
DNA polymerase
genes. It was found that the 3.0 kb HSV-R(D1) DNA fragment consisted entirely of HSV-2(186) nucleotide sequences except for the presence of 1610 bp of HSV-1(17) DNA. The 1610 bp of HSV-1 DNA coded for a 536 amino acid (AA) region which were located between AA 254 and 790 of the
DNA polymerase
enzyme. Comparison of the 536 AA sequence of neuroinvasive HSV-1(17) with the homologous area of the non-neuroinvasive HSV-2(186)
DNA polymerase
indicated that the two polymerases differed at
56 AA
positions. In addition, this area of the HSV-1(17)
DNA polymerase
was 5 AA acids shorter than the HSV-2(186)
DNA polymerase
. Specific amino acid changes that might account for the neuroinvasive phenotype of HSV-R(D1) are discussed.
...
PMID:Differences in the capacity of two herpes simplex virus isolates to spread from eye to brain map to 1610 base pairs of DNA found in the gene for DNA polymerase. 165 Jun 71
